Full video transcriptClick to expand
Auto-generated transcript of @therestoreclinic's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00testosterone replacement therapy and fertility.
- 0:03Today we're talking about kiss, pepidin 10.
- 0:05Is it good?
- 0:06Is it bad?
- 0:06Is it worth it?
- 0:07So kiss, pepidin 10 is an injectable peptide,
- 0:10typically somewhere in the ballpark of about 10
- 0:12to 15 micrograms, once a day sub-Q.
- 0:15And what it does is it increases gonadotropin
- 0:18releasing hormone.
- 0:19And what that does is it tells the brain
- 0:22to make more FSH and more LH.
- 0:24And therefore by producing those,
- 0:26your testicles are gonna make more sperm
- 0:28and testosterone respectively.
- 0:30Now that you know the mechanism of action,
- 0:32does it actually work?
- 0:33Clinically, we have not seen good results from it.
- 0:36Matter of fact, we don't prescribe it at all.
- 0:38We've had plenty of patients switch from other clinics
- 0:40who are on it and they're not quite getting
- 0:42the results they want, semen analysis sucks,
- 0:44and they're not getting the fertility results
- 0:46that they'd like.
- 0:47We've also seen some people transfer to us
- 0:49who are on kiss, pepidin monotherapy,
- 0:51and their testosterone levels
- 0:52have shown virtually no increase whatsoever.
- 0:55If you're concerned about fertility,
- 0:56stick to H, C, G, stick to H, M, G, and or F, S, H.
- 1:01But I'll tell you just like I tell every little patient,
- 1:03if you're worried about fertility,
- 1:04get a semen analysis, see where you stand, or swim.
Kisspeptin-10 on TRT: what the science actually shows
Quick answer
Men on exogenous testosterone experience suppression of the hypothalamic-pituitary-gonadal axis, reducing LH, FSH, and intratesticular testosterone, which impairs spermatogenesis. Kisspeptin-10 is being used in some telehealth and peptide clinic settings to try to restore upstream GnRH signaling, but controlled trial data in this specific population is essentially absent. HCG, HMG, and recombinant FSH have substantially stronger evidence for fertility preservation in TRT-treated men.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Kisspeptin-10 on TRT: what the science actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With HSDD: A Randomized Clinical Trial
Double-blind placebo-controlled crossover in 32 men where kisspeptin modulated sexual brain networks and increased penile tumescence versus placebo.
PubMed
Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Double-masked placebo-controlled crossover in 32 premenopausal women showing kisspeptin modulated sexual and attraction brain processing.
PubMed
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Kisspeptin-10 on TRT: what the science actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Kisspeptin-10 on TRT: what the science actually shows" from TheRestoreClinic. We read the clip as a Peptide social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Men on exogenous testosterone experience suppression of the hypothalamic-pituitary-gonadal axis, reducing LH, FSH, and intratesticular testosterone, which impairs spermatogenesis.
The reason this review is not generic is the source wording and the canonical claim label "peptides is kisspeptin 10 good on trt bhrt hrt hormones testosterone." In this clip, the useful excerpt is: "testosterone replacement therapy and fertility." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With HSDD: A Randomized Clinical Trial (2023), Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial (2022), and Direct comparison of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men (2015), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Men on exogenous testosterone experience suppression of the hypothalamic-pituitary-gonadal axis, reducing LH, FSH, and intratesticular testosterone, which impairs spermatogenesis.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Men on exogenous testosterone experience suppression of the hypothalamic-pituitary-gonadal axis, reducing LH, FSH, and intratesticular testosterone, which impairs spermatogenesis. Kisspeptin-10 is being used in some telehealth and peptide clinic settings to try to restore upstream GnRH signaling, but controlled trial data in this specific population is essentially absent. HCG, HMG, and recombinant FSH have substantially stronger evidence for fertility preservation in TRT-treated men.
- Kisspeptin-54 has human trial evidence; kisspeptin-10, the fragment most peptide clinics use, does not have comparable controlled trial data in men on TRT.
- The dosing range cited in the video (10-15 mcg daily subcutaneous) is lower than doses used in published kisspeptin studies and does not match any documented effective protocol.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Kisspeptin-54 has human trial evidence; kisspeptin-10, the fragment most peptide clinics use, does not have comparable controlled trial data in men on TRT.
- The dosing range cited in the video (10-15 mcg daily subcutaneous) is lower than doses used in published kisspeptin studies and does not match any documented effective protocol.
- Coviello et al. (2005, JCEM) found that HCG co-administration during TRT preserved intratesticular testosterone and spermatogenesis, making it the better-evidenced choice for fertility concerns.
- Kisspeptin cannot override the suppressive effect of exogenous testosterone on Leydig cells through LH stimulation alone, which likely explains why monotherapy showed no testosterone increase in the cases they described.
- A baseline semen analysis before starting any fertility intervention is standard of care and the most reliable way to understand where a patient actually stands.
- The peptide clinic market frequently uses compounds based on early-phase or animal research. Kisspeptin-10 in TRT-suppressed men is a clear example of clinical use running ahead of the evidence.
- Anecdotal clinical experience from a single clinic is not equivalent to controlled trial data, even when the conclusion happens to align with the absence of published evidence.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @therestoreclinic actually say?
The creator said kisspeptin-10 is an injectable peptide used to stimulate GnRH, which then drives LH and FSH production to support sperm and testosterone output in men on TRT. Their verdict was blunt: "clinically, we have not seen good results from it" and they "don't prescribe it at all." They recommended HCG, HMG, or FSH instead for fertility preservation, and closed by telling anyone worried about fertility to get a semen analysis first. That last point, at least, is genuinely good advice.
The mechanism they described is accurate in outline. Kisspeptin neurons in the hypothalamus do stimulate GnRH release, which triggers pituitary output of LH and FSH. Their clinical skepticism, however, is where the picture gets more complicated.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
TheRestoreClinic · TikTok creator
33.0K views on this video
Is kisspeptin-10 good on #TRT ? #bhrt #hrt #hormones #testosterone #testosteronetherapy #hashimotos #hypothyroidism
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about kisspeptin-54 has human trial evidence; kisspeptin-10, the fragment most peptide?
Kisspeptin-54 has human trial evidence; kisspeptin-10, the fragment most peptide clinics use, does not have comparable controlled trial data in men on TRT.
What does the video say about the dosing range cited in the video (10-15 mcg daily?
The dosing range cited in the video (10-15 mcg daily subcutaneous) is lower than doses used in published kisspeptin studies and does not match any documented effective protocol.
What does the video say about coviello et al. (2005, jcem) found?
Coviello et al. (2005, JCEM) found that HCG co-administration during TRT preserved intratesticular testosterone and spermatogenesis, making it the better-evidenced choice for fertility concerns.
What does the video say about kisspeptin cannot override the suppressive effect of exogenous testosterone on?
Kisspeptin cannot override the suppressive effect of exogenous testosterone on Leydig cells through LH stimulation alone, which likely explains why monotherapy showed no testosterone increase in the cases they described.
What does the video say about a baseline semen analysis before starting any fertility intervention?
A baseline semen analysis before starting any fertility intervention is standard of care and the most reliable way to understand where a patient actually stands.
What does the video say about the peptide clinic market frequently uses compounds based on early-phase?
The peptide clinic market frequently uses compounds based on early-phase or animal research. Kisspeptin-10 in TRT-suppressed men is a clear example of clinical use running ahead of the evidence.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by TheRestoreClinic, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.